The QualityStocks Daily Monday, February 5th, 2024

Today's Top 3 Investment Newsletters

MarketClub Analysis(FDMT) $32.2900 +84.62%

QualityStocks(IQST) $0.2900 +35.83%

Zacks(IPA) $2.3000 +22.34%

The QualityStocks Daily Stock List


QualityStocks and TopPennyStockMovers reported earlier on iQSTEL Inc. (IQST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

iQSTEL Inc. (OTCQX: IQST) is a holding firm that is engaged in the provision of technology and telecom solutions.

The firm has its headquarters in Coral Gables, Florida and was incorporated in 2008, on June 28th. Prior to its name change in August 2018, the firm was known as PureSnax International Inc. It operates as part of the wired and wireless telecommunications carriers’ industry. The firm serves consumers around the globe.

The company mainly operates through its USA LLC subsidiary. In total, it has seven firms in its corporate family. The company operates through the Switzerland and USA geographic segments.

The enterprise offers submarine optic fiber network capacity for internet, such as 5G and 4G; and international long-distance voice services for telecommunications operators. It also provides a blockchain technology platform focused on the telecom sector, known as ItsBchain. In addition to this, the enterprise provides domestic and international SMS termination services, short messages service and VoIP connectivity services; as well as Internet of Things services, OmniChannel marketing services, Cloud-PBX and infrastructure connectivity services, and blockchain and payment solutions. The enterprise serves small and medium, enterprise, corporate, government and wholesale carrier firms in Europe, CIS, Latin America and North America.

The firm, which is in a favorable financial position, is focused on executing its business plan, which involves the expansion of its technology products and services and the development of new services and products. This move will be good for its revenues, investments into the firm and its growth.

iQSTEL Inc. (IQST), closed Monday's trading session at $0.29, up 35.8314%, on 1,473,440 volume with 00 trades. The average volume for the last 3 months is 1.337M and the stock's 52-week low/high is $0.082 /$0.335 .

Banzai International (BNZI)

FreeRealTime reported earlier on Banzai International (BNZI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Banzai International Inc. (NASDAQ: BNZI) is a marketing technology firm engaged in the provision of data-driven marketing and sales solutions for a range of businesses in Europe, the Americas, Africa, the Middle East and the Asia Pacific.

The firm has its headquarters in Bainbridge Island, Washington and was incorporated in 2015. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe.

The company allows firms of all sizes to target, engage, and measure both new and existing customers more effectively. It is engaged in consolidating mission-critical, sub-scale marketing technology products within three key themes: acquisition, engagement, and analytics.

The enterprise’s platform products include Demio and Boost. Demio is a software as a service (SaaS) solution for webinars designed for marketing, sales, and customer success teams. Boost is a SaaS solution for social sharing designed to increase attendance for Demio-hosted events by enabling social sharing by event registrants. The enterprise sells recurring subscription licenses in SaaS businesses. Its clients represent a variety of industries, including financial services, e-commerce, technology, and others.

The firm recently signed a non-binding letter of intent to acquire Boast, an all-in-one platform for video-based customer testimonials and surveys. Boast has more than 500 clients, including Whole Foods, Blink, HubSpot, The North Face and Blue Cross Blue Shield. This move will mark the next milestone in targeted expansion of the firm’s MarTech suite and bolster its customer engagement capabilities. This is in addition to creating a new avenue to generate shareholder value.

Banzai International (BNZI), closed Monday's trading session at $1.552, up -0.512821%, on 36,535 volume with 00 trades. The average volume for the last 3 months is 6,321 and the stock's 52-week low/high is $1.46 /$16.57 .

Leatt Corp. (LEAT)

QualityStocks, MarketBeat, TopPennyStockMovers, Trades Of The Day, StocksEarning, SmallCapVoice and Nebula Stocks reported earlier on Leatt Corp. (LEAT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Leatt Corp (OTCQB: LEAT) is a company focused on designing, developing, marketing and distributing personal protective equipment for participants of motor sports and leisure activities globally.

The firm has its headquarters in Durbanville, South Africa and was incorporated in 2001 by Christopher James Leatt. Prior to its name change in May 2005, the firm was known as Treadzone Inc. It operates as part of the leisure industry, under the consumer cyclical sector. The firm serves consumers across the globe.

The enterprise’s offerings include Leatt-Brace system, an injection molded neck protection system designed to prevent injuries to the cervical spine and neck. It also offers helmets for head and brain protection; and body armor products, including full upper body protectors, chest protectors, upper body protection vests, knee braces, back protectors, knee and elbow guards, impact shorts and cooling vests, off-road motorcycle boots, and mountain biking shoes. In addition to this, the enterprise provides other products, parts, and accessories, such as goggles; toolbelt, duffel, gear, helmet, and hydration bags; casual clothing and caps; hats; and apparels that comprises suits, jackets, jerseys, pants, shorts, socks, and gloves, as well as aftermarket support products. Further, it acts as the original equipment manufacturer for neck braces sold by other brands. The enterprise’s products are used by riders of motorcycles, bicycles, snowmobiles, and ATVs, as well as motor racing cars and other helmeted sports. It sells its products to consumers through its online store at, as well as through a network of distributors and retailers.

The company recently launched a new line of adventure gear for motorcycle enthusiasts who sought comfort and safety. This move may help extend its consumer reach while also bringing in additional revenues into the company.

Leatt Corp. (LEAT), closed Monday's trading session at $8.7, up -0.571429%, on 10,718 volume with 00 trades. The average volume for the last 3 months is 2,703 and the stock's 52-week low/high is $8.55 /$19.50 .

Xinyi Solar (XNYIF)

MarketBeat reported earlier on Xinyi Solar (XNYIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Xinyi Solar Holdings Limited (OTC: XNYIF) (HKG: 0968) is an investment holding firm focused on producing and selling solar glass products.

The firm has its headquarters in Wuhu, China and was incorporated in 2006. It operates as part of the solar industry, under the technology sector. The firm serves consumers around the world, with a focus on those in the People’s Republic of China, rest of Asia, Europe and North America.

The company operates through the Sales of solar glass; Solar farm business; and Engineering procurement and construction services segments. The sales of solar glass segment is involved in the production and sale of solar glass products. The solar glass products include ultra-clear processed glass (PV) raw glass, as well as other PV processed glass such as ultra-clear PV tempered glass, ultra-clear PV anti-reflective coating glass and back glass to photovoltaic module manufacturers. The solar farm and solar power generation segment is involved in the operation of utility-scale ground mounted solar farms. On the other hand, the Engineering Procurement and Construction (EPC) services segment is engaged in the provision of EPC services for solar farms.

The enterprise provides solar power systems. At present, it has 6 major photovoltaic glass production bases, which are located in Wuhu City of Anhui province, Beihai city of Guangxi province, Zhangjiagang city of Jiangsu province, Malacca city in Malaysia, and Tianjin city in China. As at June 2023, total daily melting capacity stood at 21,800 tons.

The firm remains focused on generating value for its shareholders and bolstering its overall growth.

Xinyi Solar (XNYIF), closed Monday's trading session at $0.4064, up -15.3333%, on 14,001 volume with 00 trades. The average volume for the last 3 months is 501,791 and the stock's 52-week low/high is $0.4064 /$1.29 .

Compass Minerals International Inc. (CMP)

SmarTrend Newsletters, QualityStocks, MarketBeat, The Online Investor, DividendStocks, Daily Trade Alert, Trades Of The Day,, InvestorPlace, The Street, Kiplinger Today, MiningNewsWire, Zacks, StreetAuthority Daily, StreetInsider, Schaeffer's, All about trends, MarketClub Analysis, Barchart, BUYINS.NET, CRWEFinance, Daily Market Beat, Wyatt Investment Research, Daily Wealth, Top Pros' Top Picks, InsiderTrades, The Stock Dork and Insider Wealth Alert reported earlier on Compass Minerals International Inc. (CMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Stockholm University researchers conducting an ammonia catalyst surface study have made a breakthrough that could revolutionize fertilizer manufacturing. The scientists studied the surface of ruthenium and iron catalysts during the formation of ammonia from hydrogen and nitrogen for the first time ever and published their results in the journal “Nature.”

Their findings gave a deeper understanding of the catalytic process involved in ammonia formation and opened the door to the discovery of more efficient fertilizer materials. Ammonia is a critical base chemical in fertilizer production. It is typically produced via the Haber-Bosch process, a technique that has been referred to as humanity’s greatest scientific invention of the 20th century. The process is mostly responsible for the world’s yearly production of 110 million tons of ammonia and is credited with saving billions of lives globally by preventing mass starvation.

However, despite the critical role ammonia and fertilizers have played in advancing human civilization, the process of creating fertilizers significantly contributes to global emissions. Stockholm University professor of chemical physics Anders Nilsson says researchers have been unable to experimentally investigate the catalyst surface under real ammonia production conditions using surface-sensitive methods.

Nilsson notes that the research team at Stockholm University built a photoelectron spectroscopy device to allow them to study catalyst surfaces under high-pressure conditions. The instrument allowed the researchers to see what happens in different reactions and granted them deeper insight into ammonia production catalysis, chemical physics postdoc David Degerman says. Degerman explains that the new instrument is capable of “detecting reaction intermediaries and providing evidence of the reaction mechanism,” a feat researchers have been unable to achieve for decades.

Stockholm University researcher Patrick Lömker adds it was essential that the instrument is placed at one of the world’s brightest x-ray sources, Hamburg’s PETRA III, and says the research team can now look to a future with brighter x-ray sources once PETRA III is upgraded to PETRA IV.

According to Nilsson, researchers now have the tools they need to look for new catalyst materials in ammonia production that could help the fertilizer industry cut its emissions in line with global plans to transition to clean energy. With most major industries working to adopt renewable energy and clean technologies, especially sectors that contribute to global emissions, the fertilizer segment simply cannot be left behind.

A Cambridge University study found that both synthetic fertilizers and manure emit 2.6 gigatons of carbon each year, surpassing emissions from global shipping and aviation combined. As efforts continue to find ways to reduce these emissions, it is likely that major fertilizer manufacturers such as Compass Minerals International Inc. (NYSE: CMP) could tweak their processes to accommodate these new production technologies.

Compass Minerals International Inc. (CMP), closed Monday's trading session at $22.28, up -3.1725%, on 511,699 volume with 00 trades. The average volume for the last 3 months is 629,957 and the stock's 52-week low/high is $18.88 /$46.99 .

Compass Pathways PLC (CMPS)

InvestorBrandNetwork, QualityStocks, InvestorPlace, MarketBeat, Daily Trade Alert, Top Pros' Top Picks, StreetInsider, Schaeffer's, Trades Of The Day, The Street, PsychedelicNewsWire and Prism MarketView reported earlier on Compass Pathways PLC (CMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Several Canadian biotechnology companies are poised to make a killing in the Australian market after the county’s Therapeutic Goods Administration (TGA) allowed psychiatrists to prescribe MDMA and psilocybin in 2023. The TGA regulates therapeutic goods such as medical devices and prescription drugs in Australia. It approved the prescription of psilocybin, the main psychoactive agent in magic mushrooms, and MDMA by changing their classification in Australia’s Poisons Scheme.

The TGA’s changes to the Poisons Scheme mean that the two psychedelics are considered Schedule 8 Controlled Drugs for specific uses. However, psilocybin and MDMA will remain in Schedule 9 (Prohibited Substances), which largely restricts their supply to clinical trials. That said, the approval means that Australian psychiatrists with special authorization can now prescribe MDMA to treat post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression. With the nation preparing its Authorized Prescriber Scheme for psychedelics-based medicines, the nascent psychedelic market is completely ripe for the taking.

Biotechnology companies from Canada are set to reap big from Australia’s psychedelic segment by supplying the industry with standardized and safe good manufacturing practice-grade substances. The Authorized Prescriber Scheme is still in its infancy and recently reached a major milestone after Monarch Mental Health Group cofounder Ted Cassidy became the first physician to prescribe MDMA-assisted therapy to treat a female patient with PTSD.

Several Canada-based biotech companies with a focus on psychedelics have already completed the logistical and regulatory steps required to facilitate the export of controlled substances such as MDMA and psilocybin to Australia. Now that they have overcome the significant legal and logistical challenges involved, these Canadian companies are ready to begin shipping MDMA and psilocybin to Australia.

British Columbia-based Filament Health Corp. recently made its first export of PEX010, a botanical psilocybin drug candidate, to Perth-based Reset Mind Sciences. Filament has plenty of experience supplying drugs to specialized programs such as the Authorized Prescriber Scheme. The British-Columbia-based biotech company supplied Canada’s Special Access Program with nonmarketed drugs that aren’t available for retail sale for patients with severe or life-threatening conditions for several years.

Reset Mind Sciences will use Filament’s product for research purposes. It is currently looking to secure a GMP license application to manufacture botanically sourced psilocybin products for human consumption.

Toronto-based PharmAla Biotech is also working to supply MDMA and psilocybin to Australia’s psychedelics space. In late 2023, the company announced the completion of its first psilocybin and MDMA shipment to Australian partner Vitura Health Limited. In addition, Optimi Health Corp from Garibaldi Highlands, British Columbia, has partnered with mental-health charity and psychedelic-assisted therapy training provider Mind Medicine Australia to supply psychedelics under the Authorized Prescriber Scheme.

The opening of more international markets is likely to provide impetus to psychedelic drug developers such as Compass Pathways PLC (NASDAQ: CMPS) to speed up their R&D efforts in order to tap the growing market for drugs based on hallucinogens.

Compass Pathways PLC (CMPS), closed Monday's trading session at $11.01, up 1.1019%, on 624,289 volume with 00 trades. The average volume for the last 3 months is 36.188M and the stock's 52-week low/high is $5.01 /$12.30 .

Rivian Automotive Inc. (RIVN)

InvestorPlace, Schaeffer's, Kiplinger Today, The Street, QualityStocks, MarketBeat, MarketClub Analysis, Early Bird, INO Market Report, Investopedia, StockEarnings, The Online Investor, Zacks, Daily Trade Alert, Trades Of The Day, StocksEarning, TipRanks, AllPennyStocks, The Night Owl, Louis Navellier, GreenCarStocks, InvestorIntel, DividendStocks, InvestorsUnderground, Top Pros’ Top Picks, Top Pros' Top Picks, Cabot Wealth and bullseyeoptiontrading reported earlier on Rivian Automotive Inc. (RIVN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Chinese electric vehicle makers are stepping up their competition against industry giant Tesla by packing their cars with a range of new features. Tesla has been the top electric vehicle company in China and the global market for over a decade, but the Texas-based automaker has faced a lot of pressure from Chinese companies in recent years.

With competition in the electric vehicle sector ramping up even further, EV makers in China are adopting new technologies to make their cars stand out from the pack and attract consumers from other companies. Li Yi, CEO and chair of laser display company Appotronics, a Shenzhen-based company that claims to work with top carmakers, says electric vehicles are increasingly becoming consumer electronics. According to Yi, demand for these new vehicle technologies could help his company’s auto segment generate anywhere from $40 to $100 million per year.

While Tesla only offers limited driver-assist features and few additional accessories, carmakers in China are filling their vehicles with a wide range of tech-based accessories. Appotronics CEO Li Yi says Chinese customers are more interested in EVs with the “most advanced tech specs,” while European consumers are more concerned with functionality.

The Aito M9 SUV features collapsible front sets, a refrigerator, a 32-inch foldable screen and a projector that provides information and overlays it over the road ahead. The cost: $66,320 to $80,430. Li Auto’s L9 SUV also comes with a refrigerator, driver-assist capabilities and AR HUD at $60,553.

New Chinese EVs are now equipped with novel features such as driver assist, in-car projectors and even refrigerators. A lot of these new cars feature technology that Tesla and other top EV makers still don’t offer, and at lower price points.  This makes Chinese EVs increasingly competitive in both the Chinese and global markets, especially with high inflation and rising living costs forcing many consumers to be extra careful with their purchases. Electric cars from China tend to be cheaper compared to units made by Western companies, thanks to massive subsidies from China’s government.

These subsidies significantly reduce the high cost of EV production, allowing Chinese electric vehicle companies to pass the savings to their consumers. Tesla finally lost its status as the top-selling electric vehicle brand in the last quarter of 2023 after BYD surpassed it in sales. CEO Elon Musk has acknowledged that Chinese EV companies will be the West’s biggest competitors as the electric vehicle industry matures.

It is now incumbent upon other EV makers such as Rivian Automotive Inc. (NASDAQ: RIVN) to catch up to these new auto technologies in order to retain their market share.

Rivian Automotive Inc. (RIVN), closed Monday's trading session at $14.94, up -4.2308%, on 29,518,356 volume with 00 trades. The average volume for the last 3 months is 13.331M and the stock's 52-week low/high is $11.68 /$28.06 .

Coinbase Global Inc. (COIN)

Schaeffer's, InvestorPlace, The Street, Prfmonline, MarketClub Analysis, QualityStocks, Greenbackers, MarketBeat, Zacks, INO Market Report, Kiplinger Today, Investopedia, Early Bird, OTCPicks, SmallCapVoice, The Online Investor, Ceocast News, The Wealth Report, CoolPennyStocks, HotOTC, Daily Trade Alert, InsiderTrades, StockEgg, StockEarnings, Trades Of The Day, Stock Stars, Penny Invest, Stock Rich, StocksEarning, Top Pros' Top Picks, BestOtc, Top Gun, The Stock Psycho, CNBC Breaking News, BullRally, CryptoCurrencyWire, Wealth Daily, StockHotTips, FreeRealTime, HotShotStocks, MadPennyStocks, PennyTrader Publisher, FeedBlitz, Energy and Capital, Smartmoneytrading, PennyStockVille, Summa Money, StockRich, Today's Financial News, Profit Confidential, Stockpalooza, PennyInvest, Early Investing, AlphaShark Trading, Cabot Wealth, Atomic Trades, CRWEWallStreet, Blaque Capital Stocks, Dawn Report, BloomMoney, bullseyeoptiontrading, Eagle Financial Publications, Dynamic Wealth Report, Pennybuster, Stock Fortune Teller, wyatt research newsletter, WiseAlerts, wealthmintrplus, Wealth Whisperer, Trading with Larry Benedict, TradersPro, TipRanks, Penny Stock Finder, Stock Traders Chat, Green Chip Stocks, Stock Analyzer, Standout Stocks, Round Up the Bulls, Penny Stock Rumble, AllPennyStocks, Momentum Traders, MicrocapVoice, Louis Navellier and StockMister reported earlier on Coinbase Global Inc. (COIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Leading global payment company Visa has introduced a new way to convert cryptocurrencies into fiat money without the need for centralized exchanges. In a major move announced on Jan. 30, 2024, Visa partnered with Web3 infrastructure vendor Transak to integrate crypto payments and withdrawals into its Visa Direct product.Users can now take out crypto straight from wallets such as MetaMask onto a Visa debit card.

The integration, which is already in effect, allows for frictionless crypto-to-fiat trades at any of the 130 million Visa merchant locations worldwide. Through the partnership, customers from 145 countries including the UAE, Cyprus, Singapore, Malta, Portugal and Turkey, can directly swap more than 40 cryptocurrencies for fiat, eliminating the need for centralized exchanges.

Yanilsa Gonzalez-Ore, head of North America Visa Direct, lauded Visa Direct’s real-time withdrawals and pointed out that Transak’s solution improves user experiences by making the process of converting cryptocurrency balances into fiat money faster, easier and more connected.

According to Harshit Gangwar, head of marketing and investor relations at Transak, the partnership between Transak and Visa is significant because it broadens the opportunities for converting cryptocurrency into fiat currency. That conversion is a critical step in closing the divide between conventional finance and crypto.

Gangwar emphasized how revolutionary the integration is, calling it a significant step toward the adoption and acceptance of cryptocurrencies by the general public. Further, he noted that the integration enhances accessibility and convenience, particularly for users of decentralized wallets and platforms, includingTrust Wallet, Ledger and MetaMask.

Lorenzo Santos, senior product manager at MetaMask, acknowledged the significance of the collaboration, stating that Transak’s integration with the global payment platform offers new avenues for MetaMask users worldwide, providing enhanced flexibility when converting crypto to fiat.

The integration of Transak is supported by licenses from several jurisdictions, guaranteeing adherence to antimoney laundering and know-your-customer laws. This strong architecture, according to Gangwar, guarantees a safe and legal environment by allowing the company to authenticate users and permit transactions.

Visa has been exploring the potential applications of cryptocurrencies for a while. In 2020, the company collaborated with blockchain startup Circle to enable the USDC stablecoin on specific Visa cards. The collaboration comes at a time when cryptocurrency ownership has increased dramatically over the last 12 months. Global cryptocurrency use rose by 34% last year, with ethereum and Bitcoin being the main drivers of the rise to 580 million users globally.

This new partnership between Visa and Transak is likely to complement what exchanges such as Coinbase Global Inc. (NASDAQ: COIN) are doing to make crypto more accessible to the wider public.

Coinbase Global Inc. (COIN), closed Monday's trading session at $117.3, up -9.2246%, on 13,067,336 volume with 00 trades. The average volume for the last 3 months is 3.267M and the stock's 52-week low/high is $46.43 /$187.39 .


InvestorPlace, Schaeffer's, StockEarnings, StocksEarning, QualityStocks, MarketBeat, Trades Of The Day, Daily Trade Alert, BUYINS.NET, Kiplinger Today, The Street, StreetInsider, The Online Investor, FreeRealTime, Early Bird, CNBC Breaking News, Investopedia, MarketClub Analysis, StockMarketWatch and MarketClub reported earlier on SNDL Inc. (SNDL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, the Virginia Rehabilitation and Social Services Senate Committee passed a proposal to legalize commercial cannabis sales by a 10 to 5 vote. The bill, SB 448, introduced by Senator Aaron Rouse, aims to initiate the licensing of recreational cannabis businesses starting this July. However, retail licenses would not be accessible until next year.

Subject to voter approval, the measure gives local governments the authority to potentially outlaw commercial marijuana operations.

SB 448 will move on to the Senate’s justice committee next week. Subsequently, it will undergo evaluation in the finance committee, where a crucial deadline of Feb. 5, 2024, looms to keep it in contention. There’s also a crossover date of Feb. 13, 2024, that requires the senate to forward the bill to the house, which is also considering a marijuana sales measure of its own.

During a senate marijuana subcommittee hearing, Rouse’s bill prevailed over an opposing proposal from Senator Adam Ebbin, SB 423. Ebbin’s proposal, which aimed to accelerate adult-use marijuana sales through already-existing dispensaries, was rejected due to worries about possible market dominance by well-established companies.

SB 448 outlines licensing for five business categories, including testing laboratories, cultivators, retailers, manufacturers and transporters. The entities would fall under the regulatory purview of the state’s existing CCA.

Legislators have refrained from debating the bill’s tax components or criminal justice legislation effects thus far, delegating those discussions to the senate’s fiscal and judicial committees.

One amendment suggested during last week’s session is a definition of cultivator size measurement. Cannabis advocates suggest replacing the bill’s maximum of 2,000 plants for the largest cultivators with a cap on canopy square area. However, Rouse objected to this change, claiming that plant counts are simpler to monitor and give small companies greater flexibility.

The subcommittee meeting included a significant amount of debate on social-justice provisions, which emphasized priority licensing for veterans, hemp producers and people from low-income and over-policed communities. Changes that were covered in previous subcommittee sessions included doing away with a clause that prohibited legislators from working in the marijuana industry and forbidding law enforcement from being involved in the business. Additional changes addressed issues such as fairness standards for veterans, testing licensing restrictions to prevent lab shopping and concerns for those impacted by the drug war.

Additionally, the proposal addresses the qualifying standards for marijuana company licenses, prohibiting those with felonies or other convictions involving moral conduct from applying for seven years. There were requests to shorten this exclusion period during the subcommittee meeting.

The legislation arrives against the backdrop of Virginia’s existing legal framework, where recreational cannabis possession, use and personal cultivation are already permitted. Originally a Democrat-controlled legislation from 2021, the framework ran into difficulties due to GOP control over the governor’s office and the house later in the year. The unlicensed market has since expanded as a result of the lack of a newly adopted regulatory framework.

Even if Democrats took back control of both chambers of Congress in November, it is still difficult to pass laws on marijuana sales. There are challenges in reaching a consensus among Democrats and possible resistance from Virginia Governor Glenn Youngkin. Gov. Youngkin has voiced his distaste for cannabis reform and highlighted particular issues, such as labor union regulations for cannabis-related enterprises. Although he first seemed receptive to the notion of commercial sales, more subsequent remarks appear to indicate a change in perspective.

The entire cannabis industry, including sector players such as SNDL Inc. (NASDAQ: SNDL), hope that the launch of adult-use cannabis sales in Virginia happens on schedule so that the residents who aspire to consume this substance can find legal sources to access it.

SNDL Inc. (SNDL), closed Monday's trading session at $1.33, up -2.2059%, on 1,457,426 volume with 00 trades. The average volume for the last 3 months is 52,508 and the stock's 52-week low/high is $1.25 /$2.36 .

Solidion Technology Inc. (STI)

The Street, MarketClub Analysis, Louis Navellier, StocksEarning, Market Report, MarketBeat, Kiplinger Today, InvestorPlace, StreetInsider, Barchart, Schaeffer's, Zacks, The Street Report, Daily Trade Alert,, Trades Of The Day, Money Morning, StreetAlerts, Daily Markets, StreetAuthority Daily, Daily Wealth, Trading Concepts, SmarTrend Newsletters, TopStockAnalysts, StockEarnings, Market Intelligence Center Alert, Investopedia, Street Insider, ProfitableTrading, WStreet Market Commentary, MarketWatch, Wall Street Greek, SmallCap Network, SmallCapNetwork, FNNO Newsletters, Dividend Opportunities, The Online Investor, Investing Daily, BUYINS.NET, ChartAdvisor, Darwin Investing Network, Forbes, Eagle Financial Publications, Greenbackers, Inside Investing Daily, Hit and Run Candle Sticks, Future Source, Dynamic Wealth Report, Taipan Daily, Wealth Daily, Uncommon Wisdom, Trading Markets, Tradespoon, Total Wealth, TheTradingReport, PennyStockScholar, The Motley Fool, Money and Markets, StockMarketWatch, Stansberry Research, Shah's Insights & Indictments, Rockwell Trading, QualityStocks, OTCtipReporter, Navellier Growth and The Stock Enthusiast reported earlier on Solidion Technology Inc. (STI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Solidion Technology (NASDAQ: STI), a company that’s core business includes manufacturing of battery materials and components, as well as development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air and sea transportation, started trading today on the NASDAQ Global Market. The company represents a business combination between Honeycomb Battery Company, a leading battery materials supplier and Nubia Brand International Corp., a special purpose acquisition company led by an African-American/Latino sponsor group. According to the announcement, the transaction, which was approved at a special meeting of Nubia’s stockholders in December 2023, resulted in a company that was renamed Solidion Technology. Solidion management is confident that Honeycomb’s track record of performance and expertise in battery technologies combined with the investment by Nubia and the continued growth of the EV battery market will create an ideal opportunity for Solidion to extend its leading industry position.

“Today represents a momentous achievement for our company,” said Solidion Technology executive chair Dr. Bor Jang in the press release. “Having developed a cost-effective process for mass-manufacturing green graphite anode materials from sustainable biomass sources, Solidion’s years of in-depth R&D and manufacturing experience in graphite and other anode and cathode materials put it in a unique position to capitalize on the rapidly changing EV battery materials market. As a public company with enhanced access to capital, we plan to continue building on our extensive battery IP portfolio to further expand the range of advanced battery materials we offer and help transform the EV battery space into a solid-state battery industry.”

To view the full press release, visit

About Solidion Technology Inc.

Solidion Technology is headquartered in Dallas, Texas, with production facilities in Dayton, Ohio. The company’s core business includes manufacturing of battery materials and components, as well as development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air and sea transportation. Recognized as a global IP leader in both the high-capacity anode and the high-energy solid-state battery, Solidion is uniquely positioned to offer two lines of battery products: (i) advanced anode materials (ready for production expansion); and (ii) three classes of solid-state batteries, including Silicon-rich all-solid-state lithium-ion cells (Gen 1), anodeless lithium metal cells (Gen 2), and lithium-sulfur cells (Gen 3), all featuring an advanced polymer- or polymer/inorganic composite-based solid electrolyte that is process friendly. Solidion’s solid-state batteries can be manufactured at scale using current lithium-ion cell production facilities; this feature enables fastest time-to-market of safe solid-state batteries. Solidion batteries are designed to deliver significantly extended EV range, improved battery safety, lower cost per KWh, fastest time-to-market and next-gen cathodes. To learn more about the company, visit

Solidion Technology Inc. (STI), closed Monday's trading session at $3.03, up -33.1126%, on 111,359 volume with 00 trades. The average volume for the last 3 months is 13.945M and the stock's 52-week low/high is $2.47 /$13.85 .

IGEN Networks Corporation (IGEN)

QualityStocks, SmallCapVoice, RedChip, The Green Baron, StockGuru,, equities Canada and MarketBeat reported earlier on IGEN Networks Corporation (IGEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

IGEN Networks (OTC: IGEN) CEO Neil G. Chan is providing a status report on the company’s key initiatives; IGEN is a leading innovator of solutions for the consumer automotive, fleet management and supply-chain industries. In the update, Chan discusses new opportunities for the company, noting that IGEN has focused on the following: opportunities within the commercial side of its business; new technologies, which included offering an integrated all-in-one solution that address the SME (“SME”) business supply-chain requirements at lower costs and on a subscription basis; and new marketing channels, which involved IGEN signing a comarketing agreement with a Fortune 100 wireless carrier. “In preparation for completing these key initiatives, the company has extinguished all outstanding debt for an exchange of Preferred Series A shares with Jefferson Street Capital LLC (‘JSC’), along with JSC's continued support of IGEN through a previously announced $5 million equity line,” stated the company in the press release. “[IGEN] has also replaced all Amazon Web Services (‘AWS’)-based services with in-house infrastructure, single sourced hardware from South Korea rather than China to mitigate supply-chain risks and secured several whole-sale airtime service packages with two major U.S. wireless carriers, thereby reducing operating costs severalfold. Combined with our Fortune 100 wireless carrier, IGEN will be positioned to become the first mover on evolving opportunities for the SME supply-chain industry as we welcome 2024 and beyond.”

To view the full press release, visit

About IGEN Networks Corporation

IGEN Networks creates software services for the commercial asset management industries enabling its customers to better manage their assets and improve productivity. For more information about the company, please visit

IGEN Networks Corporation (IGEN), closed Monday's trading session at $0.0002, up 0%, on 7,625,666 volume with 00 trades. The average volume for the last 3 months is 361,922 and the stock's 52-week low/high is $0.0001 /$0.0028 .

TerrAscend Corp. (TSNDF)

QualityStocks, InvestorPlace and Cabot Wealth reported earlier on TerrAscend Corp. (TSNDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A new poll has found that the majority of voters in America are in favor of cannabis being legalized in all states. The poll conducted by the Tarrance Group involved interviews with about one thousand voters. The interviews were carried out Jan. 3–4, 2024.

The poll determined that 57% of those who responded support nationwide legalization of marijuana. Of this number, 35% admitted to strongly supporting the change in policy. It also found that roughly 55% of GOP voters aged 55 and below supported the legalization of marijuana. In addition, 74% of Democrats aged 55 and below also admitted to supporting the drug’s legalization in all states. Among independent voters, 56% stated that they were in favor of countrywide legalization of marijuana.

It should be noted that various measures have been introduced in Congress that would allow states to make their own decisions concerning marijuana while putting an end to the federal criminalization of the drug.

In an interview, U.S. Cannabis Council’s Josh Glasstetter stated that the survey’s results demonstrated that bipartisan support for the federal legalization of marijuana was growing and a generational shift on marijuana was underway. He then noted that during this year’s election, younger voters who strongly supported legalization would be sought after.

Overall, 67% of voters 18 to 44 years of age say they support a countrywide model to legalize marijuana. This is significantly higher than 57% of those aged 45 to 64 and 47% of those aged 65 and older.

Poll results noted that 68% of President Joseph Biden supporters also favor the reform with 48% of GOP members who support Donald Trump sharing these sentiments. With regard to undecided voters, 50% also support the change in policy.

This poll’s results are similar to those from a separate 2023 survey, which determined that support for ending the federal prohibition of cannabis had hit a new high nationally, with 7 in every 10 Americans supporting the reform. A different survey by Lake Research Partners also found that President Biden stood to make great political gains if cannabis was rescheduled under his administrative directive.

The survey was commissioned by the Coalition for Cannabis Scheduling Reform. The survey comes after the U.S. Department of Health and Human Services completed its scientific review in 2023 and gave its recommendation that marijuana be rescheduled. Despite this recommendation, the matter can only be decided by the DEA.

The drug’s rescheduling may not completely phase out the illicit market, however, Another poll found that nearly one-third of cannabis consumers would return to the illicit market if the drug was rescheduled and then made available solely as an approved prescription drug under the FDA.

The evolving regulatory landscape in the United States is being closely watched by companies such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) so that these companies can quickly ascertain how any changes made could impact their operations.

TerrAscend Corp. (TSNDF), closed Monday's trading session at $2.16, up -6.087%, on 408,808 volume with 00 trades. The average volume for the last 3 months is 4,513 and the stock's 52-week low/high is $1.29 /$2.39 .

The QualityStocks Company Corner

Astrotech Corp. (NASDAQ: ASTC)

The QualityStocks Daily Newsletter would like to spotlight Astrotech Corp. (NASDAQ: ASTC).

1st Detect, a wholly owned subsidiary of mass spectrometry company Astrotech, is offering its breakthrough TRACER 1000(TM) Explosive Trace Detector ("ETD") in markets that accept ECAC certification

The TRACER 1000(TM) ETD is designed to outperform ETDs currently used at airports, cargo and other secured facilities, as well as at borders

Astrotech is working to position its product as the next-generation solution for the ETD market at a time when many of the existing IMS-based ETDs are due for replacement

Keenly watching the developments in the field of explosives and narcotics detection at airports is Astrotech (NASDAQ: ASTC), a mass spectrometry company that, through its wholly owned subsidiary, 1st Detect, has developed and rolled out the breakthrough TRACER 1000(TM) Explosive Trace Detector ("ETD"). The world's first mass spectrometry-based ETD certified by the European Civil Aviation Conference ("ECAC"), the TRACER 1000(TM) is designed to outperform the ETDs currently used at aviation checkpoints as well as borders, cargo facilities, and other secured points around the world.

Astrotech Corp. (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name.

In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (ATi) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.

Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (ECAC) certification for the TRACER 1000™, the world’s first mass-spec Explosives Trace Detector (ETD) used in airports worldwide. Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.

Astrotech is headquartered in Austin, Texas.


Astrotech Technologies Inc.

Astrotech Technologies Inc. (ATi) owns and licenses the platform mass spectrometry technology originally developed by 1st Detect. This technology is designed to be less expensive, smaller and easier to use than traditional mass spectrometers.

Unlike other technologies, ATi works under high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The company’s intellectual property includes 18 granted patents, along with extensive trade secrets.

ATi exclusively licenses the Astrotech Mass Spectrometer Technology to the three wholly owned subsidiaries of Astrotech.

1st Detect Corp.

1st Detect Corp. developed the TRACER 1000, the world’s first mass spectrometry-based explosives and narcotics trace detector. 1st Detect ETDs were developed for use at airports, cargo facilities and other secured locations and borders worldwide.

1st Detect’s commercial sales of the TRACER 1000 ETD, consumables and recurring maintenance services brought in $750,000 in total revenue during the fiscal year ended June 30, 2023. The Astrotech subsidiary recently secured two orders for a total of 24 Tracer 1000 units from two Romanian security and telecommunications companies, to be delivered during calendar 2023.

AgLAB Inc.

AgLAB Inc. is developing a series of mass spectrometers for use in the hemp and cannabis market, with an initial focus on optimizing yields in the distillation processes.

AgLAB, which uses the company’s proprietary AgLAB 1000-D2™ mass spectrometer, has been proven to improve distillation oil yields and bottom-line profits for hemp and cannabis producers. During field trials, AgLAB was able to improve ending-weight yields by an average of 24%.

BreathTech Corp.

BreathTech is developing the BreathTest-1000™, a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have a compromised condition including but not limited to a bacterial or viral infection. The company believes that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

Market Opportunity

A report by Mordor Intelligence, a research and advisory firm, put the global mass spectrometry market at $6.37 billion in 2023. The market is forecast to grow to $8.63 billion by 2028, achieving a CAGR of 6.25% during the forecast period.

One of the major driving factors for the growth of the mass spectrometry market is technological advancements in mass spectrometer devices, the report states. Key market players are continuously working toward advancing their existing products and launching innovative and advanced mass spectrometer devices.

Another major factor that is expected to boost market growth is increasing research and development expenditure by both government and private entities, according to the report. Mass spectrometry devices are also being used in the detection and analysis of COVID-19 and other disease samples, which may have a positive impact on the market.

Management Team

The Astrotech leadership team includes management executives, as well as industry and technology experts. The company continues to actively expand its talent pool to meet evolving demands.

Thomas B. Pickens III is Chairman, CEO and Chief Technology Officer of Astrotech Corp. He also serves as CEO of Astrotech subsidiaries ATi, 1st Detect, AgLAB Inc. and BreathTech Corp. Previously, he was the founder and president of Beta Computer Systems Inc. and T.B. Pickens & Co. He was founder and general partner of Grace Pickens Acquisition Partners L.P and managing partner of Sumpter Partners. He also served as CEO of Catalyst Energy Corporation and United Thermal Corporation and as president of Golden Bear Corp., United Hydro Inc. and Slate Creek Corp. He received a B.A. in Economics, Computer Science and Engineering from Southern Methodist University.

Jaime Hinojosa, CPA, is CFO at Astrotech Corp. He joined the company in 2015 and has served as its Corporate Controller since 2019. His previous roles with the company include Director of Finance, from 2017 to 2019, and Assistant Controller, from 2015 to 2017. Prior to joining Astrotech, Mr. Hinojosa worked as an Accounting Manager for O’Reilly Auto Parts and gained public accounting experience as an Audit Manager at Burton McCumber & Cortez LLP.

Astrotech Corp. (NASDAQ: ASTC), closed Monday's trading session at $8.32, up 4.1315%, on 6,639 volume with 00 trades. The average volume for the last 3 months is 2.32M and the stock's 52-week low/high is $7.00 /$15.11 .

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

Arizona-based rat population control innovator SenesTech is expanding the market for its unique non-lethal, fertility-reduction products by partnering with a sustainable solutions irrigation company to roll out Evolve(TM) soft bait to open field agriculture

Rodent population increases have been widely reported in the wake of the COVID pandemic, and SenesTech's solution is easier to distribute than many poisons and doesn't carry the high risk of unintentionally harming non-target species

The company has introduced its products in the United States, Hong Kong, the Maldives, and the United Arab Emirates

SenesTech's irrigation solutions partner will initially introduce Evolve(TM) to a California dairy and almond operation, with the goal of expanding distribution to its other customers worldwide

Rodent pest control enterprise SenesTech (NASDAQ: SNES) is expanding its unique rat birth control product line through a team-up with a global leader in irrigation solutions to place SenesTech's soft bait solution into open field agriculture. SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, has entered a distribution agreement with a leading Singapore-based pest-control product manufacturer and distributor: Agro Technic PTE Ltd. According to the announcement, the agreement includes a significant initial stocking order as well as annual minimums. The product range that SenesTech provides is a "perfect fit" for the Agro Technic business model, long-term strategy and market positioning, according to Agro Technic. The company is committed to offering market solutions that are both environmentally friendly but effective. "Agro Technic is a leading manufacturer and supplier for equipment and chemicals in Singapore, with a strong presence in public-health vector control, professional pest control and plant protection," said SenesTech president and CEO Joel Fruendt in the press release. "With their focus on putting forth customized solutions to meet customers' needs in Singapore and throughout the region, they are an excellent partner for SenesTech as we address that market."

To view the full press release, visit

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.


SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Monday's trading session at $1.0701, up 18.9264%, on 1,902,245 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $15.11 /$.

Recent News


The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

Latest customer is a behavioral health care provider, operating four facilities and an outpatient program, with SOBRsafe's technology being initially installed in one facility, with greater footprint possible

SOBRsafe's next-generation transdermal technology detects and instantly reports the presence of alcohol as emitted through the user's skin. No breath, blood, or urine sample is required

SOBRsafe's technology is geared toward behavioral health, judicial and consumer markets, and for licensing and integration

SOBRsafe (NASDAQ: SOBR), a provider of transdermal alcohol detection technology that provides advanced screening and monitoring solutions for the behavioral health and justice industries, recently announced that the company's game-changing products are gaining momentum – with a fourth behavioral health care provider signing with SOBRsafe. The behavioral health care provider (name withheld for patient privacy considerations) operates four facilities and an outpatient program. The provider will initially install SOBRcheck(TM) in one facility for point-of-care screening and is evaluating the technology for expansion into its remaining facilities. The customer also plans to evaluate the wearable SOBRsure(TM) band for continuous monitoring in an outpatient scenario (

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.


The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.


With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.


SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.


SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.


Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Monday's trading session at $0.77, up 5.4795%, on 118,917 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2004 /$3.16 .

Recent News

Diamond Lake Minerals Inc. (OTC: DLMI)

The QualityStocks Daily Newsletter would like to spotlight Diamond Lake Minerals Inc. (OTC: DLMI).

Traditional investors often hold onto real world assets ("RWAs") with the expectation that their risk factors are known and manageable, while avoiding digital assets because of potential volatility and uncertainty about what actually underpins their risk factors

Utah-based Diamond Lake Minerals Inc. is building a vertically integrated portfolio of noteworthy subsidiaries that will be infused with security token offerings as digital assets bridged to RWAs

DLMI is working in conjunction with the U.S. Securities and Exchange Commission, SEC-registered digital asset exchange INX, to provide heightened security to digital offerings

DLMI's portfolio will include industry-agnostic holdings that span real estate, wireless technology, and entertainment — offering investors a variety of potential opportunities directly connected to real world assets

Salt Lake City-based Diamond Lake Minerals (OTC: DLMI) is dedicated to providing modern investors with a bridging strategy for accessing meaningful digital assets as a healthy part of their investment portfolios.

Diamond Lake Minerals Inc. (OTC: DLMI) is a multi-strategy operating company offering traditional investors an entry point to the future of digital securities. The company’s goal, through its established M&A roadmap, is to responsibly innovate and develop promising businesses that are likely to benefit from the ongoing shift toward digital assets. Through this approach, Diamond Lake Minerals provides traditional investors an opportunity to gain exposure to the emergence of regulated digital securities through a more familiar investment vehicle – the purchase of stock.

Founded in 1954 and headquartered in Salt Lake City, Diamond Lake Minerals is positioning itself as a leader in the digital asset and security token space. The company’s mission is to bring back to the public markets timeless business principles focused on healthy, sustainable growth and strong earnings with a goal of creating value for stakeholders in the modern digital world.

Diamond Lake Minerals believes the future of financial markets is set to be revolutionized by tokenization. Tokenization refers to the use of digital assets that can be traded via protocols with instantaneous settlement and reduced fees, eliminating the need for traditional clearing or settlement processes. Beyond efficiency, the emerging landscape emphasizes transparency, liquidity and security in asset management and investment.

With the backing of Esposito Intellectual Enterprises and its 20+ years of experience, Diamond Lake Minerals has access to the expertise of 110+ companies and 200+ joint ventures, along with knowledge spanning 25+ industries. The company is creating a vertically integrated ecosystem that encompasses various high-growth sectors. This integration aims to maximize operational efficiencies and profitability across all business units.

Products & Services Portfolio

Diamond Lake Minerals, guided by its strategic partnerships and future roadmap, envisions a diverse portfolio across multiple industries, as shown in the overview below. The company is poised to redefine the conglomerate model for the 21st century, with a focus on vertical integration, digital securities and sustainable growth.

Its target market segments include:

  • Fashion: DLMI seeks stakes in brands blending timeless aesthetics with tech influences.
  • Beauty: DLMI eyes partnerships with innovators elevating beauty through sustainable practices.
  • Real Estate: DLMI aims for interests in ventures modernizing property transactions via blockchain.
  • Hospitality: DLMI’s vision includes associations with enterprises enhancing guest experiences via tech integration.
  • Liquor: DLMI aspires to collaborate with unique distillers merging tradition and innovation.
  • IoT: DLMI intends to invest in solutions seamlessly connecting the digital and physical worlds.
  • Wireless: DLMI envisions stakes in wireless tech optimizing global communication.
  • Technology: DLMI plans to back pioneers driving the next tech revolution.
  • Maritime: DLMI seeks partnerships in maritime solutions emphasizing green initiatives.
  • Aviation: DLMI’s strategy includes holdings in aviation innovators focusing on efficiency.
  • Aerospace: DLMI aims to support ventures pushing boundaries in space exploration.
  • Education: DLMI collaborates with platforms revolutionizing learning through tech.
  • Charity: DLMI eyes alliances with charitable entities leveraging transparency via blockchain.
  • Healthcare: DLMI foresees investments in healthcare tech personalizing patient care.
  • TV: DLMI intends stakes in TV platforms innovating content delivery.
  • Film: DLMI aspires to support filmmakers merging storytelling with immersive tech.
  • Music: DLMI plans interests in music ventures amplifying artists through digital platforms.
  • Entertainment: DLMI targets stakes in platforms redefining entertainment paradigms.
  • IP: DLMI envisions collaborations safeguarding intellectual properties via tech solutions.
  • Data Management: DLMI seeks ventures optimizing data utilization and insights.
  • Data Storage: DLMI’s roadmap includes alliances with secure data storage solutions.
  • Streaming: DLMI intends to back streaming platforms prioritizing user experience.
  • Real World Assets: DLMI eyes investments translating tangible assets into digital value.
  • Gold & Silver: DLMI aims for stakes in platforms digitizing precious metal trading.
  • Sports: DLMI envisions collaborations enhancing sports experiences via tech integration.
  • Sports Technology: DLMI seeks ventures revolutionizing athlete performance and fan engagement.
  • Water: DLMI plans to back solutions ensuring water sustainability and accessibility.
  • Water Treatment: DLMI targets investments in eco-friendly water purification technologies.
  • Animation: DLMI eyes stakes in animation houses blending art with cutting-edge tech.
  • Studio Production: DLMI’s vision includes support for studios transforming content creation.
  • Consumer Products: DLMI seeks partnerships with brands prioritizing consumer-centric innovations.
  • Collectables: DLMI envisions collaborations with platforms digitizing unique collectibles.
  • Digital Assets: DLMI aims to invest in ventures maximizing the potential of digital ownership.
  • Web3: DLMI aspires to back pioneers ushering in the decentralized web era.
  • Identity Management: DLMI eyes solutions prioritizing user identity security in the digital space.
  • Media & Journalists: DLMI seeks alliances promoting unbiased reporting and content democratization.
  • Metaverse: DLMI envisions stakes in ventures crafting immersive virtual universes.
  • Space Economy: DLMI targets investments in ventures monetizing space exploration.
  • Modular Homes: DLMI plans interests in solutions revolutionizing home construction.
  • Financial Technology: DLMI seeks partnerships modernizing financial transactions.
  • Gaming: DLMI aims to back game developers enhancing user immersion.
  • Travel: DLMI eyes collaborations transforming travel experiences through tech.
  • Health & Wellness: DLMI’s strategy includes investments in holistic health tech solutions.
  • Augmented Reality: DLMI envisions stakes in AR platforms blurring reality and digital.
  • AI: DLMI seeks to support AI innovations humanizing tech interactions.
  • Esports: DLMI targets investments in platforms amplifying esports experiences.
  • Construction: DLMI plans to back ventures modernizing construction practices.
  • Virtual Reality: DLMI intends stakes in VR platforms offering alternate realities.
  • Retail Tech: DLMI envisions collaborations digitizing retail experiences.
  • Biotechnology: DLMI seeks ventures pushing boundaries in biotech innovations.

Market Opportunity

According to Diamond Lake Minerals’ business plan executive summary, the market for digital securities is projected to grow from $10 billion in 2022 to $1 trillion by 2028, a CAGR of 45% for the forecast period.

The global blockchain market value is expected to grow from an estimated $3 billion in 2020 to $39.7 billion by 2025, marking a CAGR of 67.3% for the period. Valued at $2.28 billion in 2021, the Security Token Offerings market is projected to grow at a CAGR of 19%. This growth is expected to be driven by the rising adoption of tokenization and the increasing prominence of STOs, especially in North America.

In addition, the global investment management market is projected to grow from a value of $100 trillion in 2020 to $178 trillion by 2025, recording a CAGR of 7.2% over the period.

Management Team

Brian J. Esposito is CEO of Diamond Lake Minerals. As founder and CEO of Esposito Intellectual Enterprises LLC, he brings over 20 years of diverse experience in sectors like manufacturing, technology, music and real estate, and is known for his global executive networking and balance sheet optimization skills.

Michael Reynolds is President and Director of Diamond Lake Minerals. With 35 years in private finance and M&A, he has been instrumental in growing companies like Herbalife through reverse acquisition, as well as elevating JB Oxford to $120 million in revenue. His expertise in operational management and business development ensures professional solutions for clients’ business interests.

Jon Karas is DLMI’s senior transaction and investment executive. As the CEO and co-founder of Akon Legacy Ventures, he structured, negotiated and closed numerous transactions focused on innovation and social impact in smart cities, blockchain, agriculture, mining and technology. He co-founded and led multiple companies in media and entertainment and was the driving force behind the development, financing and production of a broad range of film and television content.

Advisory Board

Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital and Chairman of SALT, brings to Diamond Lake Minerals unparalleled expertise in finance, technology and business strategy. He is expected to be instrumental in shaping DLMI’s strategic direction as the company continues to redefine the future of traditional and digital securities.

Larry Namer, Founder of E! Entertainment TV and President of Metan Global, boasts a remarkable career spanning more than half a century. He is an esteemed veteran of the entertainment industry, renowned for his influential contributions to cable television, live events, music and new media. He also leads LJN Media, a consulting firm known for its cross-industry expertise in technology, business and finance.

Andrew Fromm is a seasoned CEO and consultant with a focus on music publishing. He is known for his expertise in asset sales, songwriting and artist development. His extensive network extends beyond the music industry, showcasing his versatility and authority in the field.

Brandon Fugal is the Chairman of Colliers International in Utah and a former EY Entrepreneur of the Year. He has co-founded multiple ventures, including Coldwell Banker Commercial Advisors, Cypher, Axcend and Texas Growth Fund, and he is a recognized authority in real estate and entrepreneurship.

Michael Malik Sr. is a Detroit-based entrepreneur with a $750 million net worth, known for his pivotal role in legalizing gambling and developing major casino projects across the U.S., including Detroit’s MotorCity Casino and various Native American gaming ventures. He brings to Diamond Lake Minerals a wealth of experience and a proven track record in the gaming, sporting and entertainment industries spanning over five decades.

Raul Leal is an experienced CEO in the hospitality sector, known for his visionary leadership at SH Hotels & Resorts and former role at Virgin Hotels, where he secured over $500 million in funding and revolutionized guest experiences.

Agnes Budzyn, an accomplished entrepreneur and CEO of Bluedge Ventures, brings to the company a rich history in traditional finance and blockchain technology, serving on various global boards and committees. She has been recognized by the World Economic Forum and numerous institutions for her expertise and contributions to bridging legacy finance with emerging digital asset infrastructure.

Diamond Lake Minerals Inc. (OTC: DLMI), closed Monday's trading session at $5.25, up 0%, on 225 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.35 /$5.90 .

Recent News

Astiva Health

The QualityStocks Daily Newsletter would like to spotlight Astiva Health

CMS forecasts enrollment in Medicare Advantage programs will increase from 31.6 million in 2023 to 33.8 million in 2024

Astiva Health recently expanded into three Southern California counties, resulting in the company reaching the 10,000-member milestone mark

Astiva is committed to reshape healthcare delivery, increased access to quality healthcare

In a space where a growing number of individuals are qualifying for Medicare, Astiva Health is differentiating itself as a fast-growing Medicare Advantage Prescription Drug ("MAPD") health plan focused on redefining the standards of personalized and comprehensive healthcare. As an indication of its success in, Astiva company recently reached a key milestone, surpassing the 10,000-member mark (

Astiva Health is a dynamic and innovative Medicare Advantage Prescription Drug (MAPD) health plan committed to reshaping the landscape of personalized and comprehensive healthcare. The company offers full medical, drugs, and supplemental benefits for Medicare enrollees, currently serving counties in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino. This broad coverage reflects Astiva Health’s dedication to reaching a diverse demographic and addressing the healthcare needs of individuals across Southern California.

Astiva Health primarily serves a heretofore underserved Asian American and Pacific Islander population, which positions it in a critical and expanding market segment and offers substantial growth potential. The company recognizes the diverse needs within its served communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions.

Astiva Health cares about its members and works to establish lifelong relationships with them by providing a tailored approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Health is an essential key to living a good life, and Astiva Health makes it a priority to help members love the life they live.

The company’s mission is to deliver an unparalleled level of quality care to its members. Astiva Health’s Medicare Advantage plans provide lower costs and additional benefits beyond original Medicare coverage.

Founded in southern California, Astiva Health has strategically positioned itself in a region with a dynamic and diverse population. The organization’s extensive network and culturally responsive approach to healthcare make it well-suited to cater to the needs of the local community, creating a competitive advantage in the market.

The company is based in Orange, California.

Healthcare Model

Astiva Health is not just another health plan. The company considers the uniqueness of its members and, therefore, the means for delivering quality care to each one. To best serve its members, Astiva Health has developed one of the most diverse networks in southern California, offering a selection of medical, drugs, and supplemental benefits including dental, acupuncture, vision and hearing plans tailored to the specialized needs of individual members.

The company’s health plans provide increasing levels of benefits to members in the counties it serves. Astiva Health’s Customer Care Support and representatives are available to assist members with any issues.

The organization’s proactive approach to overcoming language barriers for the Vietnamese communities demonstrates a commitment to inclusivity and enhances accessibility – a key factor for future growth. The successful implementation of strategies for the Vietnamese community sets a precedent for Astiva Health’s ability to adapt and apply similar approaches to serve other ethnic groups in future expansions, broadening the potential impact of its services.

The company provides members access to experienced and dedicated providers and local pharmacies that work together with each member to pave a pathway toward better health. The company’s online directory provides members with a comprehensive list of providers to fit their specialized needs.

Astiva Health collaborates with a variety of partners who offer supplemental benefits to members beyond Medicare. Those benefits include transportation, vision, dental, hearing, fitness, tele-health, acupuncture and chiropractic. Astiva’s forward-thinking strategy not only fulfills a critical societal need but also ensures sustainable growth and transformative impact across diverse communities.

Market Opportunity

Medicare Advantage plans, since their establishment in 2008 as a lower-cost alternative for Medicare enrollees looking to save on monthly premiums, have been one of the fastest growing segments of the health insurance market.

According to a report by healthcare consultant Charts, nearly 31 million beneficiaries are enrolled in a Medicare Advantage plan in 2023, accounting for more than 48% of the total Medicare market. That represents 9.6% enrollment growth over 2022 totals, and the pace of growth is likely to continue, according to the Charts report.
Startup Medicare Advantage plans, a sector that includes Astiva Health, grew even faster for 2023, at a rate of 22% over 2022 totals.

Management Team

Dr. Tri T. Nguyen is co-founder and CEO of Astiva Health. He is a graduate of Stanford Medical School and is a board-certified expert in internal medicine, cardiovascular disease and interventional cardiology. As founder, CEO and owner/operator of Avanta IPA, he is a committed leader in healthcare. His visionary leadership, hands-on experience and deep industry knowledge uniquely position him to guide Astiva to success.

Chi Luong is CFO at Astiva Health. She founded and operates HADD Group LLC, a company managing medical clinic services, including business contracting, finance, staffing and ancillary support for several medical clinics in San Diego. She is responsible for the expansion and daily operation of the business functions of the medical clinics managed by HADD Group, and she has extensive knowledge and experience in healthcare business development.

Viet Tran has over 30 years of experience in engineering research, development and management. He has made numerous contributions to national network security and technology. He led the initial Naval Interoperability Profiles that set a solid foundation for future naval airborne network development. He also led a team of 50 engineers, doctorates and scientists delivering an airborne network system for the Navy’s first carrier-based unmanned aircraft. As Astiva Health’s Chief Operating and Technology Officer, member satisfaction has been his top priority. He is committed to protecting valuable data for Astiva members and providers. He constantly strives for leaner and more effective operations.

Tyler Diep is Vice President, Sales, Marketing and Provider Relations at Astiva Health. His responsibilities include handling special projects for the board of directors, as well as overseeing the sales, marketing and provider relations department. During his tenure, he tripled the membership of Astiva Health. He previously served as councilman and vice mayor of the City of Westminster, California. He immigrated to the U.S. with his parents and graduated from San Diego State with a bachelor’s degree in public administration.

Recent News


CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Brain tumors, which affects thousands of individuals around the globe, can be diagnosed using various imaging techniques, including magnetic resonance imaging (MRI) and computed tomography (CT) scans. Some tumors cannot be diagnosed using these techniques, however, which makes it hard for them to be detected earlier. In the United Kingdom, brain tumors kill more individuals aged 40 and below than any other cancer. Now, researchers have developed a blood test that may revolutionize the diagnosis of brain cancer. The blood test, called the TriNetra-Glio test, may help diagnose patients with different types of brain cancer earlier, which could eliminate the need to undergo invasive surgical biopsies. Earlier diagnosis would also speed up treatment and possibly increase patient rates of survival. The blood test's research was funded by Datar Cancer Genetics. Its mechanism of action involves the isolation of glial cells found circulating in the blood. If this blood test method of diagnosis for brain cancer proves itself in the field, it could enable the therapeutics made by entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to be administered a lot sooner before the disease has progressed or even metastasized.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $0.2617, up 4.68%, on 389,164 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.229 /$4.40 .

Recent News


The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

NextPlat (NASDAQ: NXPL, NXPLW), a global e-Commerce provider, is preparing for the launch of its exclusive OPKO Health-branded storefront on Alibaba Group Holding Limited's ("Alibaba")(NYSE: BABA) Tmall Global in China. The move follows the company's receipt of the initial set of approvals required to operate the store in the country. "We are pleased to reach this strategic milestone with our partners OPKO and Alibaba because we believe in the global potential of health and wellness as millions of consumers in China and around the globe continue to prioritize their wellbeing, contributing to the continued growth of this large and valuable product category. Through the launch and expansion of the OPKO Health storefront and the planned introduction of new e-commerce healthcare offerings later this year, we are executing on our plans to capitalize on the many revenue growth opportunities we see in the large global healthcare market," said Charles M. Fernandez, executive chairman and CEO of NextPlat.

To view the full press release, visit

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Monday's trading session at $1.57, up 6.0811%, on 42,764 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $1.23 /$4.26 .

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom Ltd. (NASDAQ: SPCB) is a leading global provider of traditional and digital identity solutions offering advanced safety, identification, and security products and solutions to governments. The company is proactively advancing its offender electronic monitoring solutions and services. "SuperCom offers government agencies a way to protect the victims of domestic abuse without the necessity of prolonged and expensive incarceration through advanced electronic monitoring. Since 1988, SuperCom has refined its offerings, yielding several offender monitoring solutions under its PureSecurity(TM) line, such as PureTrack(TM), PureCom(TM), PureTag(TM), PureProtect(TM), and PureBeacon(TM). These are in addition to its PureMonitor(TM) cloud-based software platform designed to deliver information, when and where it is needed. Various governments worldwide have adopted these solutions, affirming their overall effectiveness and efficiency," a recent article reads. "At SuperCom, we are dedicated to not only achieving excellent outcomes but also building enduring relationships with governments across the globe," said Ordan Trabelsi, president and CEO of SuperCom.

To view the full article, visit

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More



In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.


Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Monday's trading session at $0.22, up -0.63234%, on 50,415 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.205 /$2.695 .

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase 2a expansion portion of its Acclaim-1 clinical study of Reqorsa(R) therapy (quaratusugene ozeplasmid). The study combines Genprex's proprietary lead product candidate with AstraZeneca's Tagrisso(R) to treat patients with late-stage non-small cell lung cancer ("NSCLC"). An open-label, multicenter phase 1/2 clinical trial, the Accliam-1 trial has completed its phase 1 component and is moving on to phase 2. The company anticipates enrolling an estimated 66 patients in phase 2a, with one-half of the study participants receiving Tagrisso treatment alone and the other half receiving Tagrisso treatment and chemotherapy; the study will determine toxicity profiles of patients with different eligibility criteria, as well as efficacy and other endpoints.

There will be an interim analysis following the treatment of 19 patients in each cohort. The company plans to enroll an estimated 74 patients in the phase 2b randomized portion of the study; those patients will be randomized to receive either REQORSA and Tagrisso combination therapy or platinum-based chemotherapy with the primary endpoint of the phase 2b study being progression-free survival. Genprex plans to complete enrollment of phase 2a expansion study by the end of 2024."Advancing Acclaim-1 marks an important milestone for Genprex," said Genprex president, chairman and CEO Rodney Varner in the press release. "We are proud of the progress we have made thus far and are encouraged by REQORSA's potential to improve outcomes for patients battling NSCLC. We look forward to an interim analysis from the phase 2a study in 2025 and expect those results will further validate our novel gene therapy approach to treating lung cancer patients."

To view the full press release, visit

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Monday's trading session at $6.7, up 13.3672%, on 1,570,655 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $5.15 /$74.80 .

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

A recent blog written by Anastasia Samaras celebrates the achievement of a significant milestone for Upstream, a MERJ Exchange market and trading app, to amass a thriving community of over 12,500 users and counting, all eager to join the future of trading. "Upstream's journey to 12,500 users has been two-fold. On one end, we have a pipeline of issuers interested in dual listing on Upstream to reach a global investor base seeking secure, fair and efficient trading experiences that can trade using credit cards, debit cards, PayPal, USD, or USDC, unlocking liquidity and enhancing price discovery," Samaras writes. "As a smart contract-powered market, Upstream issuers are also taking advantage of our digital coupon (‘NFT') strategy, turning engaged shareholders into customers and loyal customers into shareholders. Issuers may launch digital coupons to their shareholders to reward them, drive buzz towards initiatives, and bring new potential customers in."

To view the full blog, visit

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.


Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (, an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News


Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, is reporting "great strides" with the production and deliveries of its Class 1 and Class 3 commercial EVs. In addition, the company is reporting that its subsidiary, Mullen Advanced Energy LLC, "), is moving forward with the installation of its battery-pack production line at its new 122,000-square-foot, high-energy facility in Fullerton, California. The company announced the new facility in November 2023; the new facility is dedicated to producing next-generation, American-made EV battery components, modules and packs. "We are steadfastly focused on production, production, production," said Mullen Automotive CEO and chair David Michery in the press release. "We are working through active purchase orders and strengthening our supply chain to make sure we are meeting customer needs. Unlike the consumer EV space, we have not experienced any slow down in demand for our vehicle lineup in the commercial EV space. We continue to make deliveries of our Class 1 and Class 3 commercial EVs as fast as they come out of our production line. We are fully committed to increasing our production capacity to meet the growing demand. We believe bringing the production of state-of-the-art battery technologies and manufacturing process in-house will enable us to reduce battery cost, limit our supply chain dependency and improve our gross profit margin per vehicle produced."

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Monday's trading session at $6.85, up -2.9745%, on 267,447 volume with 00 trades. The average volume for the last 3 months is 1.461M and the stock's 52-week low/high is $6.36 /$10012.50 .

Recent News

Renovaro BioSciences Inc. (NASDAQ: RENB)

The QualityStocks Daily Newsletter would like to spotlight Renovaro BioSciences Inc. (NASDAQ: RENB) .

Renovaro BioSciences Inc. (NASDAQ: RENB), formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by mid-2024. The company’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat, potentially including triple-negative breast cancer, head and neck cancers and mesothelioma.

Renovaro’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. Important confirmatory results from two humanized mouse models using the company’s novel dendritic cell-based therapy, independently conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA, were presented previously at two scientific conferences and were the foundation supporting a pre-IND submission to the U.S. Food and Drug Administration. Notably, Dr. Jewett’s findings from these studies consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro is headquartered in Los Angeles, California.


Renovaro’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance targeted immune response. Its lead candidate, RENB-DC11, is an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors.
Treatment with RENB-DC11 has now been shown to significantly reduce the size of human pancreatic tumors in humanized mice in three independent studies. The reduction in tumor size correlated with statistically significant increases in key components of an immune response.

Pre-IND was completed in June 2023, with IND filing forecast for first half of 2024. First in-human Phase I/IIa trials are predicted shortly after in H1 of 2024, including pancreatic and other solid tumors with poor treatment options and life-expectancy.

Renovaro believes that RENB-DC11 could represent the most promising and effective strategy to achieve life-long remission for a number of common and deadly tumors.

Other Development Candidates

In addition to its lead oncology platform, Renovaro’s development pipeline includes a platform targeting infectious diseases, including:

  • RENB-HV12 – An engineered allogeneic T-Cell vaccine, this therapeutic HIV vaccine candidate enhances immune infiltration, immune killing and immune surveillance. Potential pre-IND submission is planned for first half of 2024, with IND-submission expected in second half of 2024.
  • RENB-HV21 – Leveraging allogeneic NK plus Gamma Delta T (GDT) cells as potential therapy for HIV, ENOB-HV21 shows promising preliminary results without confounding factors. Renovaro owns an exclusive license and has completed the Pre-IND submission, with a potential IND submission and human trials expected in 2024.
  • RENB-HV01 – Caring Cross, a non-profit corporation, has shown that its proprietary CAR-T cells cure HIV in a mouse model. Studies in humans have begun. Renovaro has entered into a profit-sharing sublicense with Caring Cross and would share in profits if the product is commercialized.
  • RENB-HB01 – This therapeutic approach aims to eliminate all HBV rapidly (“seek and kill”) with a two to three dose treatment regimen. It is expected to be applicable for early disease to maximize impact with low risk of toxicity. Pre-IND comments have been received from the FDA for its AAV-delivery system.
    LOI to Merge with GEDi Cube International Ltd.

On August 9, 2023, Renovaro announced its execution of a binding, exclusive letter of intent to merge a subsidiary with cutting-edge health AI company GEDi Cube International Ltd. The combined company is expected to create a potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision in silico drug discovery.

GEDi Cube’s innovative technology, developed over nearly a decade, has already validated earlier diagnoses of lung cancer in humans at a leading university hospital. GEDi Cube has likewise created the early diagnosis technology for 12 additional cancers, including pancreatic and breast cancer.

“I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families,” Dr. Mark Dybul, CEO of Renovaro, stated in the news release.

GEDi Cube is led by CEO Craig Rhodes, who brings to that company tremendous industry experience leading life sciences groups at industry leaders Intel, Oracle and NVIDIA.

Market Opportunity

Pancreatic cancer alone is diagnosed globally in approximately 495,000 people each year, including roughly 64,000 in the U.S. Nearly 466,000 of those patients die annually, including approximately 51,000 in the U.S. Because of limited treatment options, life expectancy is very poor – with an approximately 10% patient survival rate at five years after diagnosis.

The global pancreatic cancer treatment market was valued at $2.15 billion in 2021 and is projected to grow from $2.48 billion in 2022 to $6.85 billion by 2029, according to Fortune Business Insights. That growth represents a CAGR of 15.7% for the forecast period.

A separate report from Fortune Business Insights projects that the global HIV drug market will grow from $30.46 billion in 2021 to $45.58 billion in 2028, recording a CAGR of 5.9% over the forecast period.

According to GlobalData, the value of the market for hepatitis B treatment is forecast to experience a significant increase in the coming years, with revenues expected to grow from $1.6 billion in 2022 to $10.5 billion in 2029. That represents a very rapid CAGR of 30% over the period. An estimated 296 million people suffer from the condition worldwide.

Management Team

Dr. Mark Dybul is the CEO of Renovaro. He has served as a tenured professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher and administrator, including as an architect and eventually the Global Ambassador of the U.S. President’s Emergency Plan for AIDS Relief and the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. He is a member of the U.S. National Academy of Medicine.

Luisa Puche is the company’s CFO. She has served as a senior accounting and financial advisor and president of Puche Group LLC from 2015-2019. She served in various key executive roles, including Interim Chief Accounting Officer, at Brightstar Corp., a $10 billion global wireless device services provider. Ms. Puche began her career at Ernst & Young, where she served for approximately 10 years. Leveraging her broad global audit, advisory and corporate expertise, she has provided strong cross-functional leadership experience managing small and large projects for both publicly traded and privately held companies in various industries, including a global implementation of the latest revenue recognition accounting standard for Del Monte, as well as the global implementation of their SOX-404 program.

Francois Binette, Ph.D., is the Chief Operating Officer and Executive Vice President of Research & Development at Renovaro. He has over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. His broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS and immuno-oncology. His career includes positions at Genzyme, Biosyntech, the DePuy Franchise of Johnson and Johnson, Medtronic and Lineage Cell Therapeutics. He received his Ph.D. from Laval University in Québec, followed by post-doctoral training at the Sanford-Burnham Institute in La Jolla and Harvard Medical School in Boston.

Renovaro BioSciences Inc. (NASDAQ: RENB), closed Monday's trading session at $4.34, up -1.139%, on 271,272 volume with 00 trades. The average volume for the last 3 months is 114,068 and the stock's 52-week low/high is $0.3928 /$5.25 .

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.